Session 11 – From Precision Medicine to Precision Health
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Peter and his team are responsible for defining and deploying what’s required to meet the needs of largescale genomics initiatives that enable precision medicine at a population scale. Peter currently spends much of his time focusing on Illumina’s broad partnership with Genomics England (GeL) in order to execute on the 100,000 Genomes Project and deliver whole genome sequencing into the National Health Service (NHS). Peter and his team work closely with global partners to adapt this reference architecture deployed at GeL/NHS to fit the needs of other large national, or institutional health initiatives.
Peter has been with Illumina for over twelve years and has held leadership roles in product marketing, market development and investor relations. Prior to joining Illumina, he worked at Applied Biosystems and Agilent Technologies in various corporate finance and investor relations roles. He first entered the life sciences industry on the investment side while at Howard Capital Management in New York as an equity research analyst and portfolio manager covering life sciences and technology companies. Peter holds a bachelor’s degree in History with a concentration in Environmental Science, and a master’s degree in Business Administration with a concentration in Finance and Economics.
Speech title & Synopsis
In order to achieve a vision of affordable population health, both current healthcare delivery and pharma business models, and their interactions, need to adapt. Healthcare systems the world over are stretched to a breaking point and increasingly expensive therapeutics put even more pressure in the system. To deliver to a future world of affordable precision medicine and personalized healthcare - with an increasing emphasis on prevention - molecular diagnostics, in combination with other key new disruptors e.g. involving digital health, machine learning/AI, new models of collaboration and increasing public/patient empowerment will be critical enablers.
Population genomics is not an end in itself - it is an enabler of a precision medicine / personalized and preventative healthcare future. Illumina has been actively engaging at a national and international level in order to explore this agenda. The emphasis is on using genomics at scale to deliver clinical utility, i.e. making use of what we know today about the genome, whilst at the same time engaging the research community to help unlock future value for patients. This is what is described as a ‘learning health ecosystem’, with a never-ending cycle that accelerates the translation of research insights into clinical care and back into research. Data is at its core.
Illumina has been transforming our software and informatics portfolio into an integrated platform that provides a common framework on which we can build our own solutions but also allows for others to build theirs. The presentation will describe that framework at a high level and then illustrate with an example of how Illumina can enable researchers and clinicians to address challenges with WGS in the context of rare disease.